Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05227144 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | PHASE1 | COMPLETED | 31 | — | — | Jan 6, 2022 | Mar 3, 2025 | Mar 20, 2025 | 8 | United States, Canada |
RP2D as determined by interval 3+3 dose escalation design
Safety and tolerability of ORIC-533
Safety and tolerability of ORIC-533
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ORIC-533 dosed orally, once per day of each consecutive 28-day cycle. |
| Dose Expansion | EXPERIMENTAL | RP2D dose |
| Name | Type | Description |
|---|---|---|
| ORIC-533 | DRUG | ORIC-533 once daily in consecutive 28-day cycles |
Inclusion Criteria: * Diagnosis of multiple myeloma (MM) with relapsed or refractory disease according to IMWG Criteria * Refractory to or not eligible for MM treatment regimens known to provide clinical benefit, including but not limited to an immunomodulatory agent, a proteasome inhibitor, and an...